Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01587534|
Recruitment Status : Completed
First Posted : April 30, 2012
Last Update Posted : April 15, 2015
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: Norzyme||Phase 2|
Pancreatic cancer has the worst overall prognosis with fewer than 3% of affected patients alive ﬁve years after the initial diagnosis. It is the fourth leading cause of death from cancer in Korea. 80-90% of patients have locally unresectable or advanced metastatic disease and for these patients only palliative treatment options remain. Symptoms include obstructive jaundice, duodenal obstruction, pain, and weight loss. Palliative treatment is mainly directed against the former three. Interventions to prevent (further) weight loss have as yet received little or no attention, in spite of the frequent occurrence of this symptom. About 90% of patients with pancreatic carcinoma have weight loss at the time of diagnosis. In addition, Weight loss prior to chemotherapy was found to have a prognostic effect on survival in a range of different tumor types.
There is a limited range of studies investigating the incidence of exocrine insufficiency in pancreatic cancer. Studies available indicate a high incidence of exocrine insufficiency in unresectable pancreatic cancer patients and patients before and after pancreatic cancer surgery. The previous reports showed that 68-92% of pancreatic cancer patients were exocrine insufficient. Such high incidences of exocrine insufficiency in pancreatic cancer patients support the use of pancreatic enzyme replacement therapy in this patient group. The guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinoma published in Gut promote the use of pancreatic enzyme replacement therapy to maintain weight and to increase quality of life in this patient group. However, studies evaluating the efficacy of pancreatic enzyme replacement therapy in pancreatic cancer are lacking to date. There have been no systematic reviews and only one randomized control trial involving a small sample of 21 patients with unresectable cancer of the pancreatic cancer.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||67 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Phase 2 Study of Randomized Controlled Trial of Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Experimental: pancreatic enzyme replacement therapy
The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
Other Name: placebo
No Intervention: Placebo
The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
- the change in body weight at eight weeks after the randomisation [ Time Frame: at baseline and 4, 8 week, 24 week ]the percentage change in body weight at eight weeks after the randomisation
- Frequency and intensity of abdominal pain daily [ Time Frame: at baseline and 4, 8 week, 24 week ]
- Frequency of bowel movements per day [ Time Frame: at baseline and 4, 8 week, 24 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01587534
|Korea, Republic of|
|NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‐gu,|
|Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769|
|Principal Investigator:||Sangmyung Woo, M.D||National Cancer Center|